摘要
受体络氨酸激酶c-Met/HGF途径的异常活化与细胞增殖、入侵、代谢,及许多类型肿瘤包括上消化道肿瘤的不良预后有关。c-Met和多信号通路包括肿瘤发生的特性和侵略性表型的相互作用已经获得了大量关注,表明其在癌症治疗中扮演着富有吸引力的靶点角色。最近几年,在具有潜在的临床应用的、有效的c-Met抑制剂的发展上已经做出了很大的努力,其中一个抑制剂,克唑替尼(双重c-Met/ALK抑制剂)最近被批准应用于具有ALK重排的肺癌治疗。然而有几个重要的问题关于克唑替尼潜在的抗癌作用及其在不同肿瘤类型包括上消化道癌症中发挥的可能的治疗作用的分子机制仍然有待回答。这篇综述的目的是为c-Met/HGF通路在癌症方面的关键作用及c-Met抑制剂的临床前或临床研究提供一个综述。越来越多的证据证明了c-Met抑制剂在其他恶性肿瘤上具有治疗潜力,例如胃癌和胰腺癌。但是, c-Met抑制剂活性的决定因素的识别仍然需要进一步的研究,通过分析影响c-Met和平行的癌症前通路的遗传和环境改变;导致抗c-Met药物发生的机制;被选择的患者可能从治疗中获益。这些研究在改善未来的c-Met靶向疗法在上消化道癌症治疗中的抗癌策略的选择性和有效性上是十分必要的。
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
Current Drug Targets
Title:Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Volume: 15 Issue: 14
Author(s): Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan
Affiliation:
关键词: c-Met/HGF通路,c-Met抑制剂,靶向药物耐受,上消化道肿瘤
摘要: Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved in tumorigenic-properties and invasive-phenotype has gained substantial attention, suggesting its role as an intriguing-target for cancer-therapy. In recent years, there have been considerable efforts in the development of effective c-Met inhibitors with potential clinical-applications and one of them, crizotinib (dual c-Met/ALK inhibitor), has recently been approved for lung-cancers with ALKrearrangement. However several important questions remain to be answered on the molecular mechanisms underlying the antitumor effects of crizotinib, as well as on its possible role in the treatment of different tumor types, including uppergastrointestinal- cancers. The aim of this review is to give an overview on critical role of the c-Met/HGF pathway in cancer, and the preclinical/clinical studies on c-Met inhibitors. There are accumulating evidences on therapeutic potential of c-Met inhibitors for the treatment of other malignancies, such as gastric and pancreatic cancers. However, further investigations are needed to identify determinants of the activity of c-Met inhibitors, through the analysis of genetic/ environmental alterations affecting c-Met and parallel pro-cancer pathways; mechanisms result in developing resistance to anti-c-Met agents; and selection of patients that might benefit from therapy. These studies will be essential to improve the selectivity/efficacy of future anticancer strategies of c-Met targeted-therapies in the treatment of upper gastrointestinal- cancers.
Export Options
About this article
Cite this article as:
Sharareh Gholamin, Hamid Fiuji, Mina Maftouh, Reza Mirhafez, Fatemeh Homaei Shandiz and Amir Avan , Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450115666141107105456
DOI https://dx.doi.org/10.2174/1389450115666141107105456 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Protein Biomarkers in Cancers of the Digestive Tract - a Step Towards Personalized Medicine
Current Proteomics Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member:
Current Pharmaceutical Design The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Microfluidic Devices for Cell, Tissue and Embryo Culture
Recent Patents on Regenerative Medicine Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses
Current Pharmaceutical Design Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Bioavailability Enhancement Strategies: Basics, Formulation Approaches and Regulatory Considerations
Current Drug Delivery The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Key Advances in MIP-based Sensors Applied for Cancer and Cardiovascular Biomarkers Detection
Current Topics in Medicinal Chemistry Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
Recent Patents on Anti-Cancer Drug Discovery